Buscar
Liquidia Corp
LQDAAñadir a la lista de seguimiento
84.110USD
-2.690-3.10%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
7.30BCap. mercado
336.13P/E TTM
Más Datos de Liquidia Corp Compañía
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Información de Liquidia Corp
Símbolo de cotizaciónLQDA
Nombre de la empresaLiquidia Corp
Fecha de salida a bolsaJul 26, 2018
Director ejecutivoJeffs (Roger A)
Número de empleados157
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 26
Dirección419 Davis Drive
CiudadMORRISVILLE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal27560
Teléfono19193284400
Sitio Webhttps://www.liquidia.com/
Símbolo de cotizaciónLQDA
Fecha de salida a bolsaJul 26, 2018
Director ejecutivoJeffs (Roger A)
Ejecutivos de Liquidia Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-0.33%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
449.29K
-1.02%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
184.04K
+1.30%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
122.89K
-6.14%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
64.21K
-3.23%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
58.24K
+10.10%
Mr. Rajeev Saggar, M.D.
Mr. Rajeev Saggar, M.D.
Chief Medical Officer
Chief Medical Officer
49.16K
-3.88%
Ms. Katherine (Katie) Rielly-Gauvin
Ms. Katherine (Katie) Rielly-Gauvin
Independent Director
Independent Director
26.24K
+22.42%
Dr. Joanna C. Horobin
Dr. Joanna C. Horobin
Independent Director
Independent Director
21.24K
+27.69%
Dr. Stephen M. Bloch
Dr. Stephen M. Bloch
Independent Chairman of the board
Independent Chairman of the board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
2.18M
-0.33%
Mr. Russell Schundler, J.D.
Mr. Russell Schundler, J.D.
General Counsel, Secretary
General Counsel, Secretary
449.29K
-1.02%
Mr. Jason Adair
Mr. Jason Adair
Chief Business Officer
Chief Business Officer
184.04K
+1.30%
Mr. Michael Kaseta
Mr. Michael Kaseta
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
122.89K
-6.14%
Mr. Scott Moomaw
Mr. Scott Moomaw
Chief Commercial Officer
Chief Commercial Officer
64.21K
-3.23%
Mr. Arthur S. Kirsch
Mr. Arthur S. Kirsch
Independent Director
Independent Director
58.24K
+10.10%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Liquidia Corp?
Los cinco principales accionistas de Liquidia Corp son: Dr. Roger A. Jeffs, Ph.D.
¿Cuántas instituciones poseen acciones de Liquidia Corp (LQDA)?
A fecha de 2026Q1, 439 instituciones poseen acciones de Liquidia Corp, con un valor de mercado combinado de aproximadamente 65.17M, lo que representa el 73.52% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -6796421.00.